<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24592" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mantle Cell Lymphoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lynch</surname>
            <given-names>David T.</given-names>
          </name>
          <aff>SAMMC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Koya</surname>
            <given-names>Supriya</given-names>
          </name>
          <aff>Genesis Care</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dogga</surname>
            <given-names>Sindhuja</given-names>
          </name>
          <aff>Jacobi Medical Center/ Albert Einstein College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kumar</surname>
            <given-names>Abhishek</given-names>
          </name>
          <aff>Albert Einstein College of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>David Lynch declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Supriya Koya declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sindhuja Dogga declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abhishek Kumar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24592.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) usually identified by a translocation of the CCND1 gene. The variety of morphologic variants may make this a challenging diagnosis, although most cases are uncomplicated. It typically follows an aggressive clinical course, although an indolent leukemia variant has been described. This activity illustrates the evaluation and treatment for mantle cell lymphoma and reviews the role of the interprofessional team and new management strategies in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology and staging of mantle cell lymphoma.</p></list-item><list-item><p>Describe the typical immunohistochemistry findings associated with mantle cell lymphoma.</p></list-item><list-item><p>Outline the different treatment strategies and investigational treatments in the pipeline in mantle cell lymphoma. Identifying complications associated with MCL treatments.</p></list-item><list-item><p>Explore healthcare team strategies for improving care coordination, communication, and new concepts and developments to advance mantle cell lymphoma outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24592&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24592">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24592.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs)&#x000a0;characterized by an (11,14) translocation&#x000a0;resulting in overexpression of the cyclin D1 (<italic toggle="yes">CCND1)</italic> gene. The&#x000a0;variety of morphologic variants&#x000a0;may make this a challenging diagnosis, although&#x000a0;some cases are uncomplicated. It typically follows an aggressive clinical course (aggressive MCL), although an indolent leukemia variant (indolent MCL) has been described.</p>
      </sec>
      <sec id="article-24592.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Mantle cell lymphoma is typically sporadic, but it may have a higher incidence in some families.</p>
      </sec>
      <sec id="article-24592.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma (NHL) with an annual incidence of one&#x000a0;case per 200 000 people. MCL comprises around 5% of all non-Hodgkins lymphomas. MCL is more common in men (3 to 1), and the median age at diagnosis ranges from 60 to 70 years old.&#x000a0;</p>
      </sec>
      <sec id="article-24592.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>MCL is characterized by reciprocal chromosomal translocation t(11;14)(q13:q32), resulting in the juxtapositioning of cyclin D1 locus to immunoglobulin heavy chain gene locus.<xref ref-type="bibr" rid="article-24592.r1">[1]</xref>&#x000a0;This leads to constitutive expression of cyclin D1 (CCND1), which plays a significant role in tumor cell proliferation via cell cycle dysregulation, chromosomal instability, and epigenetic regulation. Rare cases without this translocation may&#x000a0;have&#x000a0;a CCND2 or 3 translocations.<xref ref-type="bibr" rid="article-24592.r2">[2]</xref>&#x000a0;Hypothetical models of molecular subtypes have been proposed based on the cell of origin that correlates to clinical phenotypes. Arising from naive B cells that have no or limited iGVH mutations and express SOX 11 are the classical MCL or aggressive MCL. SOX 11 is a neural transcription factor&#x000a0;reported&#x000a0;to block&#x000a0;terminal B cell differentiation.<xref ref-type="bibr" rid="article-24592.r3">[3]</xref>&#x000a0; Arising from antigen-experienced B cells that have undergone IGVH somatic hypermutations and typically SOX 11 negative and genetically stable B cells are the indolent variant of MCL.<xref ref-type="bibr" rid="article-24592.r4">[4]</xref></p>
      </sec>
      <sec id="article-24592.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Although&#x000a0;only a single translocation defines MCL, there are several morphologic variations that one must know. In lymph nodes, there is often diffuse or nodular effacement of the lymph node. MCL may also show expansion of the mantle zones with a monocytoid appearance surrounding reactive germinal centers. Often pink histiocytes may be mixed with lymphoma cells (see image).&#x000a0;Pathologic exam with samples from tissue biopsy is essential for the diagnosis of MCL, which typically shows small lymphocytes with cells characterized by notched nuclei in the small cell or blastoid variant type.</p>
        <p>The cytology of the cells is highly variable&#x000a0;as well. In tissue, cells may appear small and mature with irregular nuclei, but in the blastoid variant, they may&#x000a0;appear immature with fine chromatin mimicking acute leukemia. The pleomorphic variant shows a marked variation in nuclear size and shape. The proliferation index and mitotic are also highly variable. In blood and bone marrow aspirate smears, lymphoma cells may have discrete vacuoles, which may be a clue in subtle cases.<xref ref-type="bibr" rid="article-24592.r5">[5]</xref></p>
      </sec>
      <sec id="article-24592.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The disease is typically widespread at diagnosis. The most common manifestations of MCL include extensive lymphadenopathy, fevers, night sweats, weight loss symptoms,&#x000a0;splenomegaly-related discomfort, and&#x000a0;blood count abnormalities due to bone marrow involvement and symptoms related to extranodal organ involvement.<xref ref-type="bibr" rid="article-24592.r6">[6]</xref>&#x000a0;Extranodal involvement, especially of the gastrointestinal tract, spleen, and bone marrow, is fairly common in MCL.<xref ref-type="bibr" rid="article-24592.r7">[7]</xref>&#x000a0;MCL has shared features of both indolent (incurable nature) and aggressive (aggressive clinical phenotype).&#x000a0;</p>
      </sec>
      <sec id="article-24592.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Excisional biopsy of a lymph node or an involved extranodal site is essential in the diagnosis of MCL. Laboratory exams, including CBC with differential, LDH, and beta-2 microglobulin, bone marrow biopsy, and imaging (CT or FDG-PET/CT) are also recommended as the standard diagnostic workup. Further, the Ki-67 index and mutation status of p53, ATM, and CCND1 are also important in selecting the optimal treatment. A CSF study is also necessary to rule out CNS involvement and guide appropriate management in MCL patients with a high Ki-67 index (greater than 30%),&#x000a0;blastoid variant, or neurologic symptoms.<xref ref-type="bibr" rid="article-24592.r8">[8]</xref>&#x000a0;Though&#x000a0;GI tract involvement is common in MCL, the routine endoscopic evaluation is unnecessary for all cases since it does not affect the management. But GI workup is recommended in the suspected stage I and non-bulky stage II for appropriately staging early-stage MCL.&#x000a0;</p>
        <p>Immunohistochemistry on pathology specimens plays an essential role in differentiating MCL from other NHL, including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL). MCL is&#x000a0;positive for B-cell markers (CD19, CD20, CD22, CD79a).&#x000a0; It is distinguished from other B-cell lymphomas by diffuse positivity for cyclin D1 and SOX11. SOX 11 is usually negative in indolent MCL. Rare cases are negative for cyclin D1 but&#x000a0;can still be positive for SOX11. MCL is typically negative for BCL6, CD10, and CD23 (while CLL is CD23 positive). Rare cases of MCL are CD10 positive.<xref ref-type="bibr" rid="article-24592.r9">[9]</xref>&#x000a0;Peripheral blood flow cytometry can have CD 200 expression characteristic of MCL. Testing for P53 mutation is recommended to help in the prognostication of MCL.</p>
        <p>&#x000a0;MIPI ( Mantle cell lymphoma international prognostic index) is a scoring system&#x000a0;is used to stratify the risk of patients with MCL with pneumonic APLE to remember for readers.<xref ref-type="bibr" rid="article-24592.r10">[10]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Age</p>
          </list-item>
          <list-item>
            <p>Performance status</p>
          </list-item>
          <list-item>
            <p>LDH&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Elevated white blood count&#x000a0;</p>
          </list-item>
        </list>
        <p>&#x000a0; Using these parameters, scoring calculators are available for free (online) that can help educate patients about their prognosis and expected survival based on these calculations of their survival. However, the MIPI scoring system falls short in predicting prognosis in all MCL patients. Therefore the addition of KI 67, cytogenetics, and TP 53 mutations can help improve the risk stratification of MCL.&#x000a0;</p>
        <p>High-risk MIPI score patients have median Overall survival (OS ) of 2.8 yrs, while low-risk MIPI had survival longer than 5 years.<xref ref-type="bibr" rid="article-24592.r11">[11]</xref><xref ref-type="bibr" rid="article-24592.r12">[12]</xref></p>
        <p>Typically based on symptoms and presentation, patients can be divided into indolent MCL or aggressive MCL.</p>
        <table-wrap id="article-24592.table0" position="float" orientation="portrait">
          <caption>
            <title>Table. Title</title>
          </caption>
          <table border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">
<bold>Indolent MCL</bold>
</td>
                <td rowspan="1" colspan="1">
<bold>Aggressive MCL</bold>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Asymptomatic</td>
                <td rowspan="1" colspan="1">Symptomatic (B symptoms)</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Extranodal/leukemic</td>
                <td rowspan="1" colspan="1">Usually nodal involvement</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">KI 67 less than 30%</td>
                <td rowspan="1" colspan="1">KI 67 greater than 30%</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Low MIPI score</td>
                <td rowspan="1" colspan="1">High MIPI score</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Small cells on morphology</td>
                <td rowspan="1" colspan="1">Can have blastoid cells&#x000a0;</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Usually, SOX 11 negative</td>
                <td rowspan="1" colspan="1">SOX 11 positive&#x000a0;</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Absence of 179/p53 mutation</td>
                <td rowspan="1" colspan="1">P 53 mutation/complex karyotype</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-24592.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>MCL remains a largely incurable disease with a median overall survival (OS) ranging from 1.8 to 9.4 years, depending on whether it is aggressive or indolent MCL. The choice of optimal treatment usually has its basis in the aggressiveness of the disease, performance status, age, and mantle cell international prognostic index (MIPI) score since there is no curative standard treatment established for MCL.&#x000a0;</p>
        <p>Indolent forms of MCL with low MIPI score, hypermutated IGH genes, SOX11 negativity, and non-complex karyotype may be monitored without immediate treatment. As such, watch and wait is appropriate in patients who have 1) Ki-67 = 30%, 2) maximum tumor diameter less than 3 cm, normal serum LDH level, 4) normal beta-2 microglobulin level, 5) no B symptoms, and 6) non-blastoid histology.<xref ref-type="bibr" rid="article-24592.r13">[13]</xref></p>
        <table-wrap id="article-24592.table1" position="float" orientation="portrait">
          <table border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Indolent/Asymptomatic MCL</td>
                <td rowspan="1" colspan="1">Classic/Aggressive/symptomatic MCL</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Wait and close monitoring</td>
                <td rowspan="1" colspan="1">Chemoimmunotherapy&#x000a0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>It is rare to find early stage I or non-bulky stage II that can be treated by involved field radiation alone or with nonaggressive regimens used for transplant-ineligible patients.&#x000a0;</p>
        <p>Symptomatic patients with classic MCL (aggressive MCL) that need treatments (Stage II bulky or stage III or stage IV can be classified as stem cell transplant eligible or nontransplant eligible based on performance status and comorbidities.</p>
        <table-wrap id="article-24592.table2" position="float" orientation="portrait">
          <table style="width: 510.417px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 202px;" rowspan="1" colspan="1">Stem cell transplant-eligible patients</td>
                <td style="width: 220.417px;" rowspan="1" colspan="1">Not eligible for Bone marrow transplant&#x000a0;</td>
              </tr>
              <tr>
                <td style="width: 202px;" rowspan="1" colspan="1">Chemo regimens that can be used: R CHOP, BR, Lenalidomide-Rituximab&#x000a0;</td>
                <td style="width: 220.417px;" rowspan="1" colspan="1">
<p>Aggressive chemo regimens used: RCHOP alternating with RDHAP; or NORDIC regimen ( Maxi RCHOP alternating with Rituximab and high dose Cytarabine or</p>
<p>Hyper-CVAD that includes a CHOP-like regimen alternating with high-dose methotrexate and cytarabine</p>
<p>Once in CR or very good PR, autologous stem cell transplant is recommended</p>
</td>
              </tr>
              <tr>
                <td style="width: 202px;" rowspan="1" colspan="1">Usually, maintenance with rituximab is performed after R CHOP chemo; however, no benefit exists for maintenance after the BR regimen&#x000a0;</td>
                <td style="width: 220.417px;" rowspan="1" colspan="1">Post-transplant rituximab maintenance every 8 weeks for 3 years is recommended for those in CR&#x000a0;</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone),&#x000a0;BR&#x000a0;(bendamustine, rituximab), R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin), hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high dose methotrexate and high dose cytarabine)</p>
        <p>Patients with relapsed or refractory disease require more aggressive treatment, which is typically a salvage regimen followed by HDC and autologous or allogeneic SCT.&#x000a0;Other second-line targeted agents with fewer side effects that are now FDA-approved include</p>
        <table-wrap id="article-24592.table3" position="float" orientation="portrait">
          <table style="width: 740px; height: 491px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 40px;">
                <td style="width: 185px; height: 40px;" rowspan="1" colspan="1">Second-line agents&#x000a0;</td>
                <td style="width: 132.354px; height: 40px;" rowspan="1" colspan="1">Main action</td>
                <td style="width: 118.646px; height: 40px;" rowspan="1" colspan="1">&#x000a0;How do they work&#x000a0;</td>
                <td style="width: 130px; height: 40px;" rowspan="1" colspan="1">Reference Study that led to approval and survival data&#x000a0;</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 185px; height: 26px;" rowspan="1" colspan="1">Ibrutinib, znubritinib, acalubritinib</td>
                <td style="width: 132.354px; height: 26px;" rowspan="1" colspan="1">BTK -inhibitors&#x000a0;</td>
                <td style="width: 118.646px; height: 26px;" rowspan="1" colspan="1">
<p>Inhibit constitutively activated B cell receptor (BCR) signaling through inhibiting BTK downstream from BCR in mantle cell and also&#x000a0; immunomodulatory effects on T cells</p>
<p>Acalubritinib&#x000a0;and&#x000a0; zanubrutinib bind to cysteine 481 of BTK and irreversibly inhibit target BTK; they have less action on off-targets&#x000a0;<xref ref-type="bibr" rid="article-24592.r14">[14]</xref>&#x000a0;</p>
</td>
                <td style="width: 130px; height: 26px;" rowspan="1" colspan="1">
<p>Ibrutinib: ORR 66%, PFS 12.3 months, OS 25 months&#x000a0;<xref ref-type="bibr" rid="article-24592.r15">[15]</xref><xref ref-type="bibr" rid="article-24592.r16">[16]</xref><xref ref-type="bibr" rid="article-24592.r17">[17]</xref>&#x000a0;</p>
<p>Acalubritinb PFS 20 months OS not reached at 26 month follow-up&#x000a0;<xref ref-type="bibr" rid="article-24592.r18">[18]</xref></p>
<p>Zanubrutinib ORR 84%&#x000a0;<xref ref-type="bibr" rid="article-24592.r19">[19]</xref><xref ref-type="bibr" rid="article-24592.r20">[20]</xref></p>
<p>Acalubritinib and zanubrutinib are not effective for BTK C481 S mutation&#x000a0;</p>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 185px; height: 13px;" rowspan="1" colspan="1">Venetoclax</td>
                <td style="width: 132.354px; height: 13px;" rowspan="1" colspan="1">&#x000a0;BCL 2 inhibitors&#x000a0;</td>
                <td style="width: 118.646px; height: 13px;" rowspan="1" colspan="1">BCL 2 is overexpressed in MCL, inhibition of BCL2 increases apoptosis of MCL cells</td>
                <td style="width: 130px; height: 13px;" rowspan="1" colspan="1">
<p>Venetoclax approval based on Phase I ORR 75%, CR 21%&#x000a0;in patients not previously on BTK inhibitors&#x000a0;<xref ref-type="bibr" rid="article-24592.r21">[21]</xref>&#x000a0;</p>
<p>Approved in combination with rituximab or ibrutinib</p>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 185px; height: 13px;" rowspan="1" colspan="1">Bortezomib</td>
                <td style="width: 132.354px; height: 13px;" rowspan="1" colspan="1">&#x000a0;Proteosome Inhibitor&#x000a0;</td>
                <td style="width: 118.646px; height: 13px;" rowspan="1" colspan="1">Decreases NF KB signaling, inhibiting p 27 degradation and thus cell cycle arrest&#x000a0;</td>
                <td style="width: 130px; height: 13px;" rowspan="1" colspan="1">
<p>In relapsed MCL not exposed to BTK inhibitors, single-agent bortezomib OS 23.5 months, the median time to progression was 6.7 months&#x000a0;<xref ref-type="bibr" rid="article-24592.r22">[22]</xref><xref ref-type="bibr" rid="article-24592.r23">[23]</xref></p>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 185px; height: 13px;" rowspan="1" colspan="1">
<p>Lenalidomide</p>
</td>
                <td style="width: 132.354px; height: 13px;" rowspan="1" colspan="1">Immunomodulatory agent&#x000a0;</td>
                <td style="width: 118.646px; height: 13px;" rowspan="1" colspan="1">Direct cytotoxicity on MCL cells,&#x000a0; enhancement of dendritic cells, NK, and T cell activation, and suppressing angiogenesis</td>
                <td style="width: 130px; height: 13px;" rowspan="1" colspan="1">Lenalidomide single-agent ORR 28%, duration of response&#x000a0;16.6 months months&#x000a0;<xref ref-type="bibr" rid="article-24592.r24">[24]</xref><xref ref-type="bibr" rid="article-24592.r25">[25]</xref></td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 185px; height: 13px;" rowspan="1" colspan="1">&#x000a0;Rituximab</td>
                <td style="width: 132.354px; height: 13px;" rowspan="1" colspan="1">&#x000a0;Monoclonal antibodies</td>
                <td style="width: 118.646px; height: 13px;" rowspan="1" colspan="1">Antibodies engineered for a specific receptor on B cells&#x000a0;</td>
                <td style="width: 130px; height: 13px;" rowspan="1" colspan="1">Rituximab in combination regimens is approved&#x000a0;<xref ref-type="bibr" rid="article-24592.r26">[26]</xref><xref ref-type="bibr" rid="article-24592.r27">[27]</xref></td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 185px; height: 13px;" rowspan="1" colspan="1">
<p>Polatuzumab, inotuzumab, pinatuzumab, loncastuximab and naratuximab</p>
</td>
                <td style="width: 132.354px; height: 13px;" rowspan="1" colspan="1">
<p>Antibody-drug conjugates</p>
</td>
                <td style="width: 118.646px; height: 13px;" rowspan="1" colspan="1">Anti CD79, Anti CD 22, Anti CD 19, Anti CD 37 antibody binders&#x000a0;that bind to targets and delivers cytotoxic drugs&#x000a0;</td>
                <td style="width: 130px; height: 13px;" rowspan="1" colspan="1">&#x000a0;In clinical trials&#x000a0;</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 185px; height: 13px;" rowspan="1" colspan="1">
<p>&#x000a0;Brexucabtagene autoleucel</p>
</td>
                <td style="width: 132.354px; height: 13px;" rowspan="1" colspan="1">CAR T cell (Chimeric antigen receptor T cell) therapy&#x000a0;</td>
                <td style="width: 118.646px; height: 13px;" rowspan="1" colspan="1">Autologous T cells genetically modified&#x000a0; transduced with CD 19 receptor to fight against lymphoma cells</td>
                <td style="width: 130px; height: 13px;" rowspan="1" colspan="1">ZUMA-2 ORR 87%, CR of 62% in relapsed MCL&#x000a0;<xref ref-type="bibr" rid="article-24592.r28">[28]</xref>&#x000a0;</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 185px; height: 13px;" rowspan="1" colspan="1">
<p>Blinatumomab</p>
<p>Mosunetuzumab</p>
</td>
                <td style="width: 132.354px; height: 13px;" rowspan="1" colspan="1">
<p>Bite-antibodies&#x000a0;</p>
</td>
                <td style="width: 118.646px; height: 13px;" rowspan="1" colspan="1">An antibody&#x000a0;that cross-links B cells and T cells by ligating CD3 and CD 19 /CD20&#x000a0;</td>
                <td style="width: 130px; height: 13px;" rowspan="1" colspan="1">&#x000a0;In clinical trials&#x000a0;</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 185px; height: 13px;" rowspan="1" colspan="1">
<p>Venetoclax + ibrutinib&#x000a0;</p>
</td>
                <td style="width: 132.354px; height: 13px;" rowspan="1" colspan="1">
<p>Combination BTK and BCL2 inhibitor</p>
</td>
                <td style="width: 118.646px; height: 13px;" rowspan="1" colspan="1">Inhibiting 2 pathways, BTK and BCL2, and having a synergistic effect&#x000a0;</td>
                <td style="width: 130px; height: 13px;" rowspan="1" colspan="1">AIM study CR 42-62%, OS 32 months&#x000a0;<xref ref-type="bibr" rid="article-24592.r26">[26]</xref></td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Ibrutinib, acalabrutinib, zanubrutinib, venetoclax +/- rituximab, bortezomib +/- rituximab, lenalidomide plus rituximab, ibrutinib and lenalidomide + rituximab and chimeric antigen receptor T-cells (CAR-T) received FDA approval and several other agents including BiTE antibodies, antibody-drug conjugates and are under clinical trials.&#x000a0;</p>
        <p>BCR- B cell receptor, BTK - Bruton's tyrosine kinase</p>
      </sec>
      <sec id="article-24592.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis primarily includes SLL/CLL and DLBCL. Both SLL/CLL and mantle cell lymphoma are CD5-positive, mature B-cell lymphomas and may be difficult to distinguish by flow cytometry alone. When there is positivity for CD200 and CD23, the diagnosis is most likely SLL/CLL. Mantle cell lymphoma is typically negative for CD23; it is positive for FMC7. Confirmation of MCL is typically performed by either FISH for t(11;14) or immunohistochemistry for cyclin D1 and/or SOX11. In tissue, uniform positive immunohistochemical&#x000a0;expression of B-cells by Cyclin D1 and SOX 11 supports MCL. Focal positivity for Cyclin D1 may be seen in the proliferation centers of SLL/CLL and should not prompt a diagnosis of MCL.<xref ref-type="bibr" rid="article-24592.r29">[29]</xref>&#x000a0;Diffuse large B-cell lymphoma is entertained when large cell proliferation is negative for Cyclin D1 and SOX11.</p>
        <p>When the architecture of a lymph node is intact and only shows focal involvement by atypical cyclin D1 positive cells, mantle cell neoplasia in situ may be a diagnostic consideration.</p>
      </sec>
      <sec id="article-24592.s11" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>Excisional Biopsies are recommended for diagnosis. The role&#x000a0;of surgery as treatment is not generally recommended, considering the systemic nature of this illness.</p>
      </sec>
      <sec id="article-24592.s12" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>Involved site radiation therapy (ISRT) to 24-36 Gy for stages IA and stage II A&#x000a0;MCL is recommended with or without combination chemoimmunotherapy. This recommendation is based on retrospective and anecdotal data with PFS at 5 years of 68%.<xref ref-type="bibr" rid="article-24592.r30">[30]</xref>&#x000a0;Considering the rarity of finding such early-stage MCL patients and the nonavailability of clinical trial data, ISRT is included in guidelines based on retrospective data.&#x000a0;</p>
      </sec>
      <sec id="article-24592.s13" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>Chemoimmunotherapies as frontline treatment, and targeted drugs as second-line treatments.</p>
        <p>Ongoing clinical trials are evaluating combination treatment strategies and new drugs. While it is beyond the scope of this discussion to list out all the ongoing clinical trials, we felt it is important to elucidate the concept underlying these trials as below for the readers.</p>
        <table-wrap id="article-24592.table4" position="float" orientation="portrait">
          <table style="width: 735px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 39px;">
                <td style="width: 44px; height: 39px;" rowspan="1" colspan="1">Concept</td>
                <td style="width: 44px; height: 39px;" rowspan="1" colspan="1">Combination strategy/Investigational Agent/ Maintenance</td>
                <td style="width: 77px; height: 39px;" rowspan="1" colspan="1">transplant eligible</td>
                <td style="width: 132px; height: 39px;" rowspan="1" colspan="1">Transplant ineligible&#x000a0;</td>
                <td style="width: 82.2709px; height: 39px;" rowspan="1" colspan="1">Front line&#x000a0;</td>
                <td style="width: 29.7291px; height: 39px;" rowspan="1" colspan="1">Relapsed/refractory&#x000a0;</td>
              </tr>
              <tr style="height: 85px;">
                <td style="width: 44px; height: 85px;" rowspan="1" colspan="1">
<p>Ibrutinib + Venetoclax</p>
</td>
                <td style="width: 44px; height: 85px;" rowspan="1" colspan="1">
<p>Combination Regimens&#x000a0;</p>
</td>
                <td style="width: 77px; height: 85px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 132px; height: 85px;" rowspan="1" colspan="1">
<p>yes</p>
<p>Phase III SYMPATICO trial</p>
</td>
                <td style="width: 82.2709px; height: 85px;" rowspan="1" colspan="1">yes</td>
                <td style="width: 29.7291px; height: 85px;" rowspan="1" colspan="1">&#x000a0;</td>
              </tr>
              <tr style="height: 72px;">
                <td style="width: 44px; height: 72px;" rowspan="1" colspan="1">
<p>Obintuzumab + Lenalidomide</p>
</td>
                <td style="width: 44px; height: 72px;" rowspan="1" colspan="1">
<p>Combination Regimens</p>
</td>
                <td style="width: 77px; height: 72px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 132px; height: 72px;" rowspan="1" colspan="1">yes</td>
                <td style="width: 82.2709px; height: 72px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 29.7291px; height: 72px;" rowspan="1" colspan="1">To sensitize MCL resistance to rituximab&#x000a0;</td>
              </tr>
              <tr style="height: 135px;">
                <td style="width: 44px; height: 135px;" rowspan="1" colspan="1">
<p>R-BAC after ibrutinib failure</p>
<p>(Rituximab, Bendamustine, cytarabine) ,&#x000a0;</p>
</td>
                <td style="width: 44px; height: 135px;" rowspan="1" colspan="1">
<p>Combination Regimens</p>
</td>
                <td style="width: 77px; height: 135px;" rowspan="1" colspan="1">yes</td>
                <td style="width: 132px; height: 135px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 82.2709px; height: 135px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 29.7291px; height: 135px;" rowspan="1" colspan="1">To bridge to an allo transplant</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 44px; height: 26px;" rowspan="1" colspan="1">CDK4/6 Inhibitor</td>
                <td style="width: 44px; height: 26px;" rowspan="1" colspan="1">Investigational Agents</td>
                <td style="width: 77px; height: 26px;" rowspan="1" colspan="1">&#x000a0;yes</td>
                <td style="width: 132px; height: 26px;" rowspan="1" colspan="1">yes&#x000a0;</td>
                <td style="width: 82.2709px; height: 26px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 29.7291px; height: 26px;" rowspan="1" colspan="1">To get deeper responses.</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 44px; height: 26px;" rowspan="1" colspan="1">&#x000a0;Lenalidomide&#x000a0;</td>
                <td style="width: 44px; height: 26px;" rowspan="1" colspan="1">Maintenance</td>
                <td style="width: 77px; height: 26px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 132px; height: 26px;" rowspan="1" colspan="1">&#x000a0;yes</td>
                <td style="width: 82.2709px; height: 26px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 29.7291px; height: 26px;" rowspan="1" colspan="1">To increase the time to relapse</td>
              </tr>
              <tr style="height: 39px;">
                <td style="width: 44px; height: 39px;" rowspan="1" colspan="1">Bortezomib combination to&#x000a0;transplant</td>
                <td style="width: 44px; height: 39px;" rowspan="1" colspan="1">Maintenance</td>
                <td style="width: 77px; height: 39px;" rowspan="1" colspan="1">&#x000a0;yes</td>
                <td style="width: 132px; height: 39px;" rowspan="1" colspan="1">&#x000a0;yes</td>
                <td style="width: 82.2709px; height: 39px;" rowspan="1" colspan="1">&#x000a0;yes</td>
                <td style="width: 29.7291px; height: 39px;" rowspan="1" colspan="1">To get deeper responses and to reduce relapse</td>
              </tr>
              <tr style="height: 52px;">
                <td style="width: 44px; height: 52px;" rowspan="1" colspan="1">Chemotherapy-free options</td>
                <td style="width: 44px; height: 52px;" rowspan="1" colspan="1">Combination of ibrutinib with obinutuzumab and venetoclax</td>
                <td style="width: 77px; height: 52px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 132px; height: 52px;" rowspan="1" colspan="1">&#x000a0;yes</td>
                <td style="width: 82.2709px; height: 52px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 29.7291px; height: 52px;" rowspan="1" colspan="1">To reduce chemo toxicity in elderly patients</td>
              </tr>
              <tr style="height: 78px;">
                <td style="width: 44px; height: 78px;" rowspan="1" colspan="1">Risk adapted approaches</td>
                <td style="width: 44px; height: 78px;" rowspan="1" colspan="1">Measuring Ct DNA and MRD status by ASO-PCR and evaluating maintenance treatments based on that&#x000a0;&#x000a0;</td>
                <td style="width: 77px; height: 78px;" rowspan="1" colspan="1">&#x000a0;yes</td>
                <td style="width: 132px; height: 78px;" rowspan="1" colspan="1">&#x000a0;yes</td>
                <td style="width: 82.2709px; height: 78px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 29.7291px; height: 78px;" rowspan="1" colspan="1">To reduce toxicity and have personalized treatments</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>MRD: Minimal residual disease; ASO-PCR: allele-specific oligonucleotide PCR; ctDNA: circulating tumor DNA.</p>
      </sec>
      <sec id="article-24592.s14" sec-type="Staging">
        <title>Staging</title>
        <p>Initial staging requires comprehensive scanning, including a contrast CT chest/abdomen/pelvis and/or whole-body PET/CT scan, along with a bone marrow biopsy with aspirate to assess the burden of disease.</p>
        <p>The staging system that is used for non-Hodgkin's lymphomas is used for the staging of MCL.</p>
        <table-wrap id="article-24592.table5" position="float" orientation="portrait">
          <table border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">Stage I&#x000a0;</td>
                <td rowspan="1" colspan="1">Involvement of one lymph node or&#x000a0;group of adjacent lymph nodes or one extra lymphatic site&#x000a0;</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Stage II</td>
                <td rowspan="1" colspan="1">Involvement of two or more nodal groups on the same side of the diaphragm or stage I or II with contiguous extranodal involvement</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Stage III</td>
                <td rowspan="1" colspan="1">Involvement of lymph nodes on either side of the diaphragm</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Stage IV</td>
                <td rowspan="1" colspan="1">involvement of bone marrow or noncontiguous extranodal involvement</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-24592.s15" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Although International Prognostic Index (IPI) failed to show prognostic power in MCL, MCL IPI (MIPI) that incorporates age, performance status, normalized LDH level, and white blood cell (WBC) count, was shown to discriminate MCL patients into three risk groups; low, intermediate, and high with a five-year overall survival (OS) of 60%, 35%, and 20%, respectively. Two other prognostic indexes were developed recently to accommodate the prognostic impact of Ki-67 (MIPIb) and simplify calculation (sMIPI), although they require further clinical validation.<xref ref-type="bibr" rid="article-24592.r31">[31]</xref> Further, CDKN2A and TP53 deletions showed inferior OS independent to Ki-67 in patients treated with autologous stem cell transplant (SCT), and TP53 overexpression was shown to correlate with a worse prognosis.<xref ref-type="bibr" rid="article-24592.r32">[32]</xref>&#x000a0; Patients who present with involvement of the peripheral blood and bone marrow (leukemic non-nodal MCL) may follow an indolent course.<xref ref-type="bibr" rid="article-24592.r33">[33]</xref></p>
      </sec>
      <sec id="article-24592.s16" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of the MCL due to the disease process itself based on the site of MCL involvement include splenic rupture due to splenomegaly, GI bleeding or obstruction or perforation due to MCL in the gastrointestinal tract, and tumor lysis in the blastoid variant of MCL are all the considerations.<xref ref-type="bibr" rid="article-24592.r34">[34]</xref>&#x000a0;Due to chemotherapy and stem cell transplants, complications of life-threatening infections, neutropenic sepsis, cytopenias needing transfusions, nausea, vomiting, and hair loss are possible.&#x000a0;With targeted&#x000a0;drug approvals in MCL with agents like ibrutinib, aBTK inhibitor, hypertension, arrhythmias, diarrhea, skin rashes, and bleeding risk are reported. These side effects are felt to be more related to off-target actions on EGFR, ITK, and PI3K. Second-generation BTK inhibitors like acalabrutinib and zanubrutinib are more specific to BTK and have fewer off-target side effects in terms of hypertension, arrhythmias, or rashes.<xref ref-type="bibr" rid="article-24592.r14">[14]</xref>&#x000a0;BCL-2 inhibitor venetoclax is now approved for MCL venetoclax drug tumor lysis syndrome, while lenalidomide edema, cytopenias, risk of blood clots, and diarrhea are expected&#x000a0;complications and or side effects to be aware of. Brexucabtagene (CAR-T cell therapy ) is associated with encephalopathy, cytopenias, and pyrexia from cytokine release syndrome, which must be addressed during the treatments.</p>
        <p>ITK - Interleukin-2-inducible T-cell kinase, EGFR-epidermal growth factor inhibitor, PI3K-phosphoinositide 3-kinase.</p>
      </sec>
      <sec id="article-24592.s17" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultations with a medical oncologist, bone marrow transplant team, and clinical trial teams are an integral part of the management of aggressive MCL.</p>
      </sec>
      <sec id="article-24592.s18" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>Mantle cell lymphoma is a rare and conventionally aggressive B-cell lymphoma with a heterogeneous disease profile.</p>
          </list-item>
          <list-item>
            <p>Cases are typically diagnosed with diffuse cyclin D1 positivity by immunohistochemistry or FISH for t(11;14).</p>
          </list-item>
          <list-item>
            <p>Rare cases that are negative for cyclin D1 for t(11;14) are positive for SOX11 by immunohistochemistry.</p>
          </list-item>
          <list-item>
            <p>High Ki67 proliferation index and p53 mutations are adverse prognostic findings and likely imply the need for more prompt treatment and clinical trial enrollment if no good response.</p>
          </list-item>
          <list-item>
            <p>Chemoimmunotherapy is conventionally the choice as front-line therapy among patients necessitating treatment with a potential role of&#x000a0;targeted therapies in the salvage setting.</p>
          </list-item>
          <list-item>
            <p>The role of autologous and allogeneic bone marrow transplant and stratifying patients as transplant eligible and ineligible in choosing the treatment choices are elucidated.</p>
          </list-item>
          <list-item>
            <p>The role of second-generation drugs in improving outcomes and the side effects of these drugs are discussed.</p>
          </list-item>
          <list-item>
            <p>Investigational new drugs alone and in combination are described.&#x000a0; Risk-adapted approaches in the pipeline for improving the care of mantle cell lymphoma patients are discussed.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24592.s19" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Mantle cell lymphoma is typically an uncomplicated diagnosis, but morphologic variants may mimic other lymphoid neoplasms. Having a low threshold for ordering additional testing for&#x000a0;cyclin D 1, SOX 11&#x000a0;immunohistochemistry, or&#x000a0;confirmatory FISH studies will prevent misdiagnosis. The disorder is best managed by an interprofessional team that includes a hematologist-medical oncologist, internist, radiologist, radiation-oncologist, bone marrow transplant team, experienced nursing staff, and clinical trial teams. It is important to recognize the indolent form of MCL that might require monitoring with aggressive forms that require immediate systemic treatments. With the availability now of multiple second-line treatments in relapsed settings, including CAR-T cell treatments recognizing the complications and side effects related to these treatments can help guide the management of MCL patients effectively.</p>
      </sec>
      <sec id="article-24592.s20">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24592&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24592">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/mantle-cell-lymphoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24592">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24592/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24592">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-24592.s21">
        <fig id="article-24592.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Mantle Cell Lymphoma. High power H&#x00026;E of mantle cell lymphoma showing monotonous mature lymphocytes with mildly irregular nuclei. A pink histocyte is highlighted by the black arrow. Contributed by D Lynch, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mantle" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-24592.s22">
        <title>References</title>
        <ref id="article-24592.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>The pathologic diagnosis of mantle cell lymphoma.</article-title>
            <source>Histol Histopathol</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>10</issue>
            <fpage>1037</fpage>
            <page-range>1037-1051</page-range>
            <pub-id pub-id-type="pmid">34114641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weisenburger</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Greiner</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Dave</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rosenwald</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chiorazzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gesk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siebert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Jong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Delabie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dave</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Sanger</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Rimsza</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Braziel</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Hermelink</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gascoyne</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Staudt</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>WC</given-names>
              </name>
              <collab>Lymphoma/Leukemia Molecular Profiling Project</collab>
            </person-group>
            <article-title>Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.</article-title>
            <source>Blood</source>
            <year>2005</year>
            <month>Dec</month>
            <day>15</day>
            <volume>106</volume>
            <issue>13</issue>
            <fpage>4315</fpage>
            <page-range>4315-21</page-range>
            <pub-id pub-id-type="pmid">16123218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vegliante</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Palomero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Gal&#x000e1;n</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rou&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Castellano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moros</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Su&#x000e1;rez-Cisneros</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Be&#x000e0;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Enjuanes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jares</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Villamor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Colomer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-Subero</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Amador</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>Mar</month>
            <day>21</day>
            <volume>121</volume>
            <issue>12</issue>
            <fpage>2175</fpage>
            <page-range>2175-85</page-range>
            <pub-id pub-id-type="pmid">23321250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Navarro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Be&#x000e0;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jares</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Molecular Pathogenesis of Mantle Cell Lymphoma.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>795</fpage>
            <page-range>795-807</page-range>
            <pub-id pub-id-type="pmid">32861278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lynch</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Foucar</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Discrete vacuoles in lymphocytes as a subtle clue to mantle cell lymphoma.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>Jun</month>
            <day>23</day>
            <volume>127</volume>
            <issue>25</issue>
            <fpage>3292</fpage>
            <pub-id pub-id-type="pmid">28092871</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Argatoff</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Klasa</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Horsman</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Gascoyne</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Mantle cell lymphoma: a clinicopathologic study of 80 cases.</article-title>
            <source>Blood</source>
            <year>1997</year>
            <month>Mar</month>
            <day>15</day>
            <volume>89</volume>
            <issue>6</issue>
            <fpage>2067</fpage>
            <page-range>2067-78</page-range>
            <pub-id pub-id-type="pmid">9058729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Romaguera</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Hagemeister</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Fayad</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Pro</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Younes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarris</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Dang</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Samaniego</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Gagneja</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Cabanillas</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma.</article-title>
            <source>Cancer</source>
            <year>2003</year>
            <month>Feb</month>
            <day>01</day>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>586</fpage>
            <page-range>586-91</page-range>
            <pub-id pub-id-type="pmid">12548600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rosenwald</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bernd</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Loddenkemper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barth</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Brousse</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rymkiewicz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kodet</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Forstpointner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thieblemont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hallek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coiffier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vehling-Kaiser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bouabdallah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kanz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pfreundschuh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ribrag</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hiddemann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Unterhalt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kluin-Nelemans</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hermine</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dreyling</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Klapper</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.</article-title>
            <source>J Clin Oncol</source>
            <year>2016</year>
            <month>Apr</month>
            <day>20</day>
            <volume>34</volume>
            <issue>12</issue>
            <fpage>1386</fpage>
            <page-range>1386-94</page-range>
            <pub-id pub-id-type="pmid">26926679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Saksena</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases.</article-title>
            <source>Oncotarget</source>
            <year>2018</year>
            <month>Feb</month>
            <day>20</day>
            <volume>9</volume>
            <issue>14</issue>
            <fpage>11441</fpage>
            <page-range>11441-11450</page-range>
            <pub-id pub-id-type="pmid">29545910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geisler</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Kolstad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laurell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>R&#x000e4;ty</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jerkeman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nordstr&#x000f6;m</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kimby</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Boesen</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Nilsson-Ehle</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kuittinen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lauritzsen</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Ralfkiaer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ehinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sundstr&#x000f6;m</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Delabie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Karjalainen-Lindsberg</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Elonen</surname>
                <given-names>E</given-names>
              </name>
              <collab>Nordic Lymphoma Group</collab>
            </person-group>
            <article-title>The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Feb</month>
            <day>25</day>
            <volume>115</volume>
            <issue>8</issue>
            <fpage>1530</fpage>
            <page-range>1530-3</page-range>
            <pub-id pub-id-type="pmid">20032504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoster</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prognostic relevance of clinical risk factors in mantle cell lymphoma.</article-title>
            <source>Semin Hematol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>48</volume>
            <issue>3</issue>
            <fpage>185</fpage>
            <page-range>185-8</page-range>
            <pub-id pub-id-type="pmid">21782060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dreyling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klapper</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gisselbrecht</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van Hoof</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kluin-Nelemans</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Pfreundschuh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reiser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Metzner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Einsele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Peter</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>W&#x000f6;rmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>D&#x000fc;hrsen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Eimermacher</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wandt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hasford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hiddemann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Unterhalt</surname>
                <given-names>M</given-names>
              </name>
              <collab>German Low Grade Lymphoma Study Group (GLSG)</collab>
              <collab>European Mantle Cell Lymphoma Network</collab>
            </person-group>
            <article-title>A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.</article-title>
            <source>Blood</source>
            <year>2008</year>
            <month>Jan</month>
            <day>15</day>
            <volume>111</volume>
            <issue>2</issue>
            <fpage>558</fpage>
            <page-range>558-65</page-range>
            <pub-id pub-id-type="pmid">17962512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Watch and Wait in Mantle Cell Lymphoma.</article-title>
            <source>Hematol Oncol Clin North Am</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>837</fpage>
            <page-range>837-847</page-range>
            <pub-id pub-id-type="pmid">32861281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barf</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Covey</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van de Kar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gulrajani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Lith</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van Hoek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Zwart</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mittag</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Demont</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verkaik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krantz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Ulrich</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kaptein</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>363</volume>
            <issue>2</issue>
            <fpage>240</fpage>
            <page-range>240-252</page-range>
            <pub-id pub-id-type="pmid">28882879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Auer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kahl</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Jurczak</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Romaguera</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Barrientos</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Chmielowska</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stilgenbauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dreyling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jedrzejczak</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Spurgeon</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baher</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Beaupre</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Rule</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.</article-title>
            <source>Blood</source>
            <year>2015</year>
            <month>Aug</month>
            <day>06</day>
            <volume>126</volume>
            <issue>6</issue>
            <fpage>739</fpage>
            <page-range>739-45</page-range>
            <pub-id pub-id-type="pmid">26059948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dreyling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jurczak</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jerkeman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Rusconi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Trneny</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Offner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Caballero</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Joao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Witzens-Harig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bence-Bruckler</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Bothos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Enny</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Traina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Balasubramanian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bandyopadhyay</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vermeulen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rizo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rule</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Feb</month>
            <day>20</day>
            <volume>387</volume>
            <issue>10020</issue>
            <fpage>770</fpage>
            <page-range>770-8</page-range>
            <pub-id pub-id-type="pmid">26673811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rule</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dreyling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Auer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kahl</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cavazos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Clow</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Beaupre</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vermeulen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wildgust</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.</article-title>
            <source>Br J Haematol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>179</volume>
            <issue>3</issue>
            <fpage>430</fpage>
            <page-range>430-438</page-range>
            <pub-id pub-id-type="pmid">28832957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rule</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Goy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Casasnovas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Damaj</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Doorduijn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lamy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Morschhauser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Panizo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dupuis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kater</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Le Gouill</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oberic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Robak</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Covey</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dua</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hamdy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rothbaum</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Slatter</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Jurczak</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.</article-title>
            <source>Lancet</source>
            <year>2018</year>
            <month>Feb</month>
            <day>17</day>
            <volume>391</volume>
            <issue>10121</issue>
            <fpage>659</fpage>
            <page-range>659-667</page-range>
            <pub-id pub-id-type="pmid">29241979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Elstrom</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Novotny</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.</article-title>
            <source>Clin Cancer Res</source>
            <year>2020</year>
            <month>Aug</month>
            <day>15</day>
            <volume>26</volume>
            <issue>16</issue>
            <fpage>4216</fpage>
            <page-range>4216-4224</page-range>
            <pub-id pub-id-type="pmid">32461234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tam</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Opat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cull</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Munoz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Rule</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Atwal</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Novotny</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trotman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.</article-title>
            <source>Blood Adv</source>
            <year>2021</year>
            <month>Jun</month>
            <day>22</day>
            <volume>5</volume>
            <issue>12</issue>
            <fpage>2577</fpage>
            <page-range>2577-2585</page-range>
            <pub-id pub-id-type="pmid">34152395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davids</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Kenkre</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Wierda</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kipps</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salem</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Pesko</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Arzt</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mantas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.</article-title>
            <source>Clin Cancer Res</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>27</volume>
            <issue>17</issue>
            <fpage>4690</fpage>
            <page-range>4690-4695</page-range>
            <pub-id pub-id-type="pmid">34083230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kahl</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Djulbegovic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>de Vos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Epner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lonial</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nasta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Boral</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>RI</given-names>
              </name>
            </person-group>
            <article-title>Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.</article-title>
            <source>Ann Oncol</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>520</fpage>
            <page-range>520-5</page-range>
            <pub-id pub-id-type="pmid">19074748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fisher</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kahl</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Djulbegovic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>de Vos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Epner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Krishnan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lonial</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stadtmauer</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Boral</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Goy</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2006</year>
            <month>Oct</month>
            <day>20</day>
            <volume>24</volume>
            <issue>30</issue>
            <fpage>4867</fpage>
            <page-range>4867-74</page-range>
            <pub-id pub-id-type="pmid">17001068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Kalayoglu Besisik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Drach</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ramchandren</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cicero</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Witzig</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.</article-title>
            <source>J Clin Oncol</source>
            <year>2013</year>
            <month>Oct</month>
            <day>10</day>
            <volume>31</volume>
            <issue>29</issue>
            <fpage>3688</fpage>
            <page-range>3688-95</page-range>
            <pub-id pub-id-type="pmid">24002500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Vose</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Czuczman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Reeder</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Haioun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Polikoff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tilly</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Prandi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Witzig</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.</article-title>
            <source>Ann Oncol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>11</issue>
            <fpage>2892</fpage>
            <page-range>2892-7</page-range>
            <pub-id pub-id-type="pmid">24030098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wagner-Bartak</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hagemeister</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Westin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fayad</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Samaniego</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Turturro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Badillo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nomie</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>DeLa Rosa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Addison</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Champlin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Romaguera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-56</page-range>
            <pub-id pub-id-type="pmid">26640039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamm</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kaufmann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Raderer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chott</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zielinski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Drach</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.</article-title>
            <source>Haematologica</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>96</volume>
            <issue>7</issue>
            <fpage>1008</fpage>
            <page-range>1008-14</page-range>
            <pub-id pub-id-type="pmid">21486866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Munoz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Locke</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Timmerman</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jaglowski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Flinn</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>McSweeney</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Miklos</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Pagel</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kersten</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Milpied</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Topp</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Houot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Beitinjaneh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Reagan</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Apr</month>
            <day>02</day>
            <volume>382</volume>
            <issue>14</issue>
            <fpage>1331</fpage>
            <page-range>1331-1342</page-range>
            <pub-id pub-id-type="pmid">32242358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teixeira Mendes</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Attygalle</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Wotherspoon</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cyclin D1 overexpression in proliferation centres of small lymphocytic lymphoma/chronic lymphocytic leukaemia.</article-title>
            <source>J Clin Pathol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>70</volume>
            <issue>10</issue>
            <fpage>899</fpage>
            <page-range>899-902</page-range>
            <pub-id pub-id-type="pmid">28408436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leitch</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Gascoyne</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Chhanabhai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Voss</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Klasa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Limited-stage mantle-cell lymphoma.</article-title>
            <source>Ann Oncol</source>
            <year>2003</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>1555</fpage>
            <page-range>1555-61</page-range>
            <pub-id pub-id-type="pmid">14504058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dreyling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferrero</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vogt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Klapper</surname>
                <given-names>W</given-names>
              </name>
              <collab>European Mantle Cell Lymphoma Network</collab>
            </person-group>
            <article-title>New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature?</article-title>
            <source>Clin Cancer Res</source>
            <year>2014</year>
            <month>Oct</month>
            <day>15</day>
            <volume>20</volume>
            <issue>20</issue>
            <fpage>5194</fpage>
            <page-range>5194-206</page-range>
            <pub-id pub-id-type="pmid">25320369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eskelund</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Dahl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Westman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kolstad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Montano-Almendras</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Husby</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Freiburghaus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Niemann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>R&#x000e4;ty</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Geisler</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Guldberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jerkeman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gr&#x000f8;nb&#x000e6;k</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title><italic>TP53</italic> mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Oct</month>
            <day>26</day>
            <volume>130</volume>
            <issue>17</issue>
            <fpage>1903</fpage>
            <page-range>1903-1910</page-range>
            <pub-id pub-id-type="pmid">28819011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maddocks</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Update on mantle cell lymphoma.</article-title>
            <source>Blood</source>
            <year>2018</year>
            <month>Oct</month>
            <day>18</day>
            <volume>132</volume>
            <issue>16</issue>
            <fpage>1647</fpage>
            <page-range>1647-1656</page-range>
            <pub-id pub-id-type="pmid">30154113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24592.r34">
          <label>34</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Sapkota</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shaikh</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <chapter-title>Non-Hodgkin Lymphoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">32644754</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
